Establishment Labs Holdings Inc. (ESTA)
| Market Cap | 2.03B +137.8% |
| Revenue (ttm) | 229.58M +34.9% |
| Net Income | -43.74M |
| EPS | -1.48 |
| Shares Out | 29.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 578,429 |
| Open | 71.30 |
| Previous Close | 71.50 |
| Day's Range | 66.86 - 72.70 |
| 52-Week Range | 33.35 - 83.31 |
| Beta | 1.12 |
| Analysts | Strong Buy |
| Price Target | 87.14 (+25.96%) |
| Earnings Date | May 6, 2026 |
About ESTA
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides breast tissue expanders. The company sells products to physicians, hospitals, and clinics through distributors and its direct sales force. Establishment Labs Holdings Inc. was incorporated in 2004 and i... [Read more]
Financial Performance
In 2025, ESTA's revenue was $211.08 million, an increase of 27.14% compared to the previous year's $166.03 million. Losses were -$51.06 million, -39.64% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for ESTA stock is "Strong Buy." The 12-month stock price target is $87.14, which is an increase of 25.96% from the latest price.
News
Establishment Labs price target raised to $90 from $88 at BTIG
BTIG raised the firm’s price target on Establishment Labs (ESTA) to $90 from $88 and keeps a Buy rating on the shares. The company’s results were driven by continued U.S.
Establishment Labs price target raised to $76 from $65 at Citi
Citi analyst Joanne Wuensch raised the firm’s price target on Establishment Labs (ESTA) to $76 from $65 and keeps a Neutral rating on the shares. The firm says this was…
Establishment Labs Holdings Earnings Call Transcript: Q1 2026
Q1 2026 saw 45% revenue growth, gross margin expansion to 70.7%, and strong U.S. momentum, driven by Motiva adoption and minimally invasive platform launches. Guidance was raised for 2026, with continued profitability and cash flow positive expected in H2.
Establishment Labs Reports First Quarter 2026 Financial Results
NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in bre...
Weight-loss revolution sparks new appetite for aesthetics firms
Aesthetic firms are betting that a growing pool of patients experiencing loose skin and facial volume loss from GLP-1 obesity drugs will fuel a new wave of demand, as the sector heads into first-quart...
Establishment Labs refinances credit facility
Establishment Labs (ESTA) entered into a $300M senior secured term loan facility with funds managed by Oaktree Capital Management. The amended and restated facility refinances the company’s existing d...
Establishment Labs® Refinances Credit Facility
NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in bre...
Establishment Labs® to Announce First Quarter 2026 Financial Results on May 6
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...
Establishment Labs surpasses more than 5M Motiva devices in market
Establishment Labs (ESTA) Holding announced that it has surpassed more than five million Motiva devices in market. “Surpassing five million Motiva devices is another milestone for our company, and a…
Establishment Labs® Surpasses More Than Five Million Motiva® Devices in Market
NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in bre...
Establishment Labs price target lowered to $65 from $74 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Establishment Labs (ESTA) to $65 from $74 and keeps a Neutral rating on the shares. The firm adjusted targets in…
Establishment Labs selloff ‘unwarranted and overdone,’ says Mizuho
Mizuho says Establishment Labs (ESTA) shares are down 28% since February 28, the first day of the U.S.-Iran conflict, which is “unwarranted and overdone.” Establishment has pulled back on concerns…
Establishment Labs price target lowered to $74 from $81 at Citi
Citi lowered the firm’s price target on Establishment Labs (ESTA) to $74 from $81 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical technology…
Establishment Labs Holdings Transcript: TD Cowen 46th Annual Health Care Conference
2025 saw exceptional U.S. growth for Motiva, driven by innovative marketing, premium pricing, and strong account expansion. 2026 guidance projects continued momentum, new product launches, and margin expansion, with international and reconstruction segments poised for further growth.
Establishment Labs price target raised to $90 from $85 at Canaccord
Canaccord raised the firm’s price target on Establishment Labs (ESTA) to $90 from $85 and keeps a Buy rating on the shares. The firm updated its model to reflect ESTA’s…
Establishment Labs price target raised to $90 from $85 at Stephens
Stephens analyst Mason Carrico raised the firm’s price target on Establishment Labs (ESTA) to $90 from $85 and keeps an Overweight rating on the shares. The firm sees a multi-year…
Establishment Labs price target raised to $90 from $85 at Stephens
Stephens analyst Mason Carrico raised the firm’s price target on Establishment Labs (ESTA) to $90 from $85 and keeps an Overweight rating on the shares. The firm sees a multi-year…
Establishment Labs price target raised to $95 from $88 at TD Cowen
TD Cowen analyst Joshua Jennings raised the firm’s price target on Establishment Labs (ESTA) to $95 from $88 and keeps a Buy rating on the shares. The firm said revenues…
Establishment Labs price target raised to $100 from $90 at Mizuho
Mizuho raised the firm’s price target on Establishment Labs (ESTA) to $100 from $90 and keeps an Outperform rating on the shares. The firm upped estimates following the company’s Q4…
Establishment Labs Holdings Earnings Call Transcript: Q4 2025
Q4 2025 saw revenue surge 45% year-over-year, with strong US and international growth, gross margins above 70%, and a significant turnaround to positive adjusted EBITDA. 2026 guidance projects 25%+ revenue growth, continued margin expansion, and cash flow positivity.
Establishment Labs CFO Raj Denhoy to switch roles, Cassandra Harris to succeed
Establishment Labs (ESTA) announced a leadership transition of Raj Denhoy, current CFO to senior VP, global strategy, and the appointment of Cassandra Harris to senior VP and CFO, effective March…
Establishment Labs Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...
Establishment Labs Announces Leadership Transition to Support Next Phase of Growth
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...
Establishment Labs to Present at TD Cowen's 46th Annual Health Care Conference
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...
Establishment Labs to Announce Fourth Quarter 2025 Financial Results on February 24
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...